A Teva-Mylan Tie-Up Would Face Serious Antitrust Scrutiny
Teva Pharmaceutical Industries Ltd.'s $50 billion takeover bid for fellow generic-drug maker Mylan NV on Tuesday marked the start of what could be a long road ahead for both sides, and experts say...To view the full article, register now.
Already a subscriber? Click here to view full article